Status:
COMPLETED
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymph...
Detailed Description
ctDNA in diffuse large B cell lymphoma (DLBCL) has become an essential dynamic biomarker. Due to its short half-life, ctDNA is a real-time reflection of tumoral evolution and is a non-invasive biomark...
Eligibility Criteria
Inclusion
- 18 years or older
- Diffuse Large B Cell Lymphoma
- TEP-TDM at diagnosis
- Inform Consent form signed
- Performance status 0 or 1
- Hospitalized on clinician decision for first cycle of R-CHOP or R-miniCHOP
Exclusion
- Histology other than Diffuse Large B Cell
- Patient under guardianship or curatorship
- Incapacity to understand the study or conform to the constraints of the study (language barrier, psychological barrier, geographic barrier…)
Key Trial Info
Start Date :
December 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06141772
Start Date
December 21 2023
End Date
April 10 2025
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France, 76000